Dow Jones

39,164.06

0.09%

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

ELTX

Elicio Therapeutics (ELTX)

Elicio Therapeutics Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ELTX

1 2 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
27/06/2024	15:05	GlobeNewswire Inc.	Elicio Therapeutics Announces Proposed Public Offering	NASDAQ:ELTX	Elicio Therapeutics Inc
27/06/2024	15:01	GlobeNewswire Inc.	Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P	NASDAQ:ELTX	Elicio Therapeutics Inc
18/06/2024	07:30	GlobeNewswire Inc.	Elicio Therapeutics Reports Inducement Grants	NASDAQ:ELTX	Elicio Therapeutics Inc
11/06/2024	23:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ELTX	Elicio Therapeutics Inc
03/06/2024	16:24	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ELTX	Elicio Therapeutics Inc
03/06/2024	15:41	Edgar (US Regulatory)	Form S-3/A - Registration statement under Securities Act of 1933: [Amend]	NASDAQ:ELTX	Elicio Therapeutics Inc
23/05/2024	16:30	GlobeNewswire Inc.	Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting	NASDAQ:ELTX	Elicio Therapeutics Inc
15/05/2024	15:34	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ELTX	Elicio Therapeutics Inc
15/05/2024	15:30	GlobeNewswire Inc.	Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates	NASDAQ:ELTX	Elicio Therapeutics Inc
25/04/2024	07:30	GlobeNewswire Inc.	Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting	NASDAQ:ELTX	Elicio Therapeutics Inc
05/04/2024	15:30	GlobeNewswire Inc.	Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting	NASDAQ:ELTX	Elicio Therapeutics Inc
29/03/2024	07:30	GlobeNewswire Inc.	Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates	NASDAQ:ELTX	Elicio Therapeutics Inc
18/03/2024	07:00	GlobeNewswire Inc.	Elicio Therapeutics Announces $6.0 Million Private Placement Financing	NASDAQ:ELTX	Elicio Therapeutics Inc
05/02/2024	07:30	GlobeNewswire Inc.	Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	NASDAQ:ELTX	Elicio Therapeutics Inc
25/01/2024	08:00	GlobeNewswire Inc.	Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors	NASDAQ:ELTX	Elicio Therapeutics Inc
17/01/2024	07:30	GlobeNewswire Inc.	Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium	NASDAQ:ELTX	Elicio Therapeutics Inc
16/01/2024	07:30	GlobeNewswire Inc.	Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference	NASDAQ:ELTX	Elicio Therapeutics Inc
11/01/2024	07:30	GlobeNewswire Inc.	Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study	NASDAQ:ELTX	Elicio Therapeutics Inc
09/01/2024	05:00	GlobeNewswire Inc.	Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002	NASDAQ:ELTX	Elicio Therapeutics Inc
22/12/2023	08:00	GlobeNewswire Inc.	Elicio Therapeutics Announces $7.0 Million Private Placement Financing	NASDAQ:ELTX	Elicio Therapeutics Inc
04/12/2023	07:00	GlobeNewswire Inc.	Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference	NASDAQ:ELTX	Elicio Therapeutics Inc
09/11/2023	15:30	GlobeNewswire Inc.	Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates	NASDAQ:ELTX	Elicio Therapeutics Inc
03/11/2023	15:30	GlobeNewswire Inc.	Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting	NASDAQ:ELTX	Elicio Therapeutics Inc
11/10/2023	07:00	GlobeNewswire Inc.	Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting	NASDAQ:ELTX	Elicio Therapeutics Inc
27/09/2023	16:30	GlobeNewswire Inc.	Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer	NASDAQ:ELTX	Elicio Therapeutics Inc
07/09/2023	07:00	GlobeNewswire Inc.	Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines	NASDAQ:ELTX	Elicio Therapeutics Inc
06/09/2023	07:00	GlobeNewswire Inc.	Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:ELTX	Elicio Therapeutics Inc
05/09/2023	07:00	GlobeNewswire Inc.	Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer	NASDAQ:ELTX	Elicio Therapeutics Inc
28/08/2023	07:00	GlobeNewswire Inc.	Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics	NASDAQ:ELTX	Elicio Therapeutics Inc
11/08/2023	07:30	GlobeNewswire Inc.	Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates	NASDAQ:ELTX	Elicio Therapeutics Inc